IOWA ONCOLOGY RESEARCH ASSOCIATION
[ Home ] [ Treatment ] [ Control & Prevention ] [ STAR ] [ SELECT ] [ Physicians ] [ Contact Us ] [ Helpful Links ]

Hematologic Cancer Research Studies

NON-HODGKIN'S
E3404    A Response-Adapted Therapy for Aggressive non-Hodgkin's Lymphomas Based on Early [¹⁸F] FDG-PET Scanning

H6Q-MC-JCBJ    A Phase III Clinical Study to Investigate the Prevention of Relapse in Lymphoma Using Daily Enzastaurin

N0682    A Phase II Clinical Trial of Denileukin Diftitox in Combination with Rituximab in Previously Untreated Follicular B-cell Non-Hodgkin's Lymphoma

SMALL LYMPHOCYTIC LEUKEMIA
N0683   A Phase II Study of Sunitinib Malate for Treatment of Patients with Relapsed / Refractory Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Lymphoma (SLL)

MANTLE CELL LYMPHOMA
E1405    A Phase II Study of VcR-CVAD with Rituximab Consolidation and Maintenance for Untreated Mantle Cell Lymphoma

N038H    Phase II Study of CCI-779 in Combination with Rituximab in Patients with Relapsed or Refractory Mantle Cell Lymphoma

PERIPHERAL T-CELL OR NK CELL NEOPLASMS
E2404   Bevacizumab and CHOP (A-CHOP) in Combination for Patients with Peripheral T-Cell or NK Cell Neoplasms

ACUTE PROMYELOCYTIC LEUKEMIA
S0521   A Randomized Trial of Maintenance Versus Observation for Patients with Previously Untreated Low and Intermediate Risk Acute Promyelocytic Leukemia (APL), Phase III

MYELOMA
E1A05    Randomized Phase III Trial of Consolidation Therapy with Bortezomib (Velcade®)- Lenalidomide (Revlimid®)- Dexamethasone (VRD) Versus Bortezomib- Dexamethasone (VD) for Patients with Multiple Myeloma Who Have Completed a Dexamethasone Based Induction Regimen

E1A06   An Intergroup Phase III Randomized Controlled Trial Comparing Melphalan, Prednisone and Thalidomide Versus Melphalan, Prednisone and Lenalidomide in Newly Diagnosed Myeloma Patients who are Not Candidates for High-Dose Therapy

CHRONIC LYMPHOCYTIC LEUKEMIA
10404   A Randomized Phase II Study of Three Fludarabine / Antibody Combinations for Patients with Symptomatic, Previously Untreated Chronic Lymphocytic Leukemia

C10501   A Phase III Intergroup CLL Study of Asymptomatic Patients with Untreated Chronic Lymphocytic Leukemia Randomized to Early Intervention Versus Observation with Later Treatment in the High Risk Genetic Subset with IgV_h Unmutated Disease

E2903   A Phase II Trial of Pentostatin, Cyclophosphamide and Rituximab (PCR) Followed by Campath-1H for Previously Treated Relapsed of Refractory Patients with Chronic Lymphocytic Leukemia

N0683   A Phase II Study of Sunitinib Malate for Treatment of Patients with Relapsed / Refractory Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Lymphoma (SLL)

ACUTE MYELOID LEUKEMIA
E2902   A Phase III Study of Farnesyl Transferase Inhibitor R115777 in AML Patients in Second or Subsequent Remission or in Remission After Primary Induction Failure

C10603   A Phase III Randomized, Double-Blind Study of Induction (Daunorubicin / Cytarabine) and Consolidation (High-Dose Cytarabine) Chemotherapy + Midostaurin or Placebo in Newly Diagnosed Patients < 60 Years of Age with FLT3 Mutated Acute Myeloid Leukemia (AML)

S0106   A Phase III Study of the Addition of Gemtuzumab Ozogamicin (Mylotarg®) During Induction Therapy Versus Standard Induction with Daunomycin and Cytosine Arabinoside Followed by Consolidation and Subsequent Randomization to Post-Consolidation Therapy with Gemtuzumab Ozogamicin (Mylotarg®) or No Additional Therapy for Patients Under Age 56 with Previously Untreated De Novo Acute Myeloid Leukemia (AML)

ACUTE LYMPHOBLASTIC LEUKEMIA
10403   An Intergroup Phase II Clinical Trial for Adolescents and Young Adults with Untreated Acute Lymphoblatsic Leukemia (ALL)